Trials / Terminated
TerminatedNCT02784795
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3039478 | Administered orally |
| DRUG | Taladegib | Administered orally |
| DRUG | Abemaciclib | Administered orally |
| DRUG | Cisplatin | Administered IV |
| DRUG | Gemcitabine | Administered IV |
| DRUG | Carboplatin | Administered IV |
| DRUG | LY3023414 | Administered orally |
Timeline
- Start date
- 2016-11-04
- Primary completion
- 2018-08-09
- Completion
- 2020-02-13
- First posted
- 2016-05-27
- Last updated
- 2025-08-21
- Results posted
- 2025-08-21
Locations
11 sites across 4 countries: United States, Denmark, France, Spain
Source: ClinicalTrials.gov record NCT02784795. Inclusion in this directory is not an endorsement.